KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Finished Goods (2018 - 2025)

Alnylam Pharmaceuticals' Finished Goods history spans 8 years, with the latest figure at $32.3 million for Q4 2025.

  • For Q4 2025, Finished Goods rose 22.34% year-over-year to $32.3 million; the TTM value through Dec 2025 reached $32.3 million, up 22.34%, while the annual FY2025 figure was $32.3 million, 22.34% up from the prior year.
  • Finished Goods reached $32.3 million in Q4 2025 per ALNY's latest filing, down from $38.8 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $38.8 million in Q3 2025 to a low of $7.0 million in Q4 2021.
  • Average Finished Goods over 5 years is $23.6 million, with a median of $25.4 million recorded in 2022.
  • Peak YoY movement for Finished Goods: crashed 44.81% in 2021, then surged 265.54% in 2022.
  • A 5-year view of Finished Goods shows it stood at $7.0 million in 2021, then soared by 265.54% to $25.6 million in 2022, then dropped by 1.89% to $25.1 million in 2023, then increased by 5.21% to $26.4 million in 2024, then increased by 22.34% to $32.3 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Finished Goods are $32.3 million (Q4 2025), $38.8 million (Q3 2025), and $33.7 million (Q2 2025).